人工T細胞の世界市場 - 世界の産業規模、シェア、動向、機会、予測、2018年～2028年、タイプ別、用途別、エンドユーザー別、地域別、競合別

世界の人工T細胞市場は、予測期間中に目覚ましい成長を遂げると予測されています。

世界の人工T細胞市場は、特にCAR-T（Chimeric Antigen Receptor T-cell）療法やTCR-T（T-cell Receptor T-cell）療法など、人工T細胞に基づく治療法の開発、製造、商業化に特化した製薬・バイオテクノロジー産業セグメントを指します。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の人工T細胞市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別（キメラ抗原受容体、T細胞受容体、腫瘍浸潤リンパ球）
  • 用途別（乳がん、大腸がん、白血病、肺がん、黒色腫）
  • エンドユーザー別（がん研究センター、クリニック、病院、その他）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第6章 北米の人工T細胞市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の人工T細胞市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋の人工T細胞市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の人工T細胞市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの人工T細胞市場の展望

• 市場規模および予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• 事業概要
• 提供製品
• 近年の発展
• 財務
• 主要人材
• SWOT分析
  • Amgen Inc
  • Athenex, Inc.
  • Bellicum Pharmaceuticals Inc
  • Bristol-Myers Squibb Co
  • Eli Lilly & Co
  • Gilead Sciences Inc
  • Novartis AG
  • Oxford Biomedica PLC
  • Pfizer Inc
  • Precision BioSciences Inc

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Engineered T Cells Market is anticipated to project impressive growth in the forecast period. The global engineered T cells market refers to the pharmaceutical and biotechnology industry segment dedicated to the development, manufacturing, and commercialization of therapies based on engineered T cells, particularly CAR-T (Chimeric Antigen Receptor T-cell) and TCR-T (T-cell Receptor T-cell) therapies.

Key Market Drivers

Advancements in Immunotherapy Research

Immunotherapy research has emerged as a beacon of hope in the realm of healthcare, offering new avenues to combat various diseases, most notably cancer. Among the many branches of immunotherapy, engineered T cell therapies, including CAR-T (Chimeric Antigen Receptor T-cell) and TCR-T (T-cell Receptor T-cell) therapies, have garnered considerable attention. The continuous advancements in immunotherapy research are now serving as a catalyst for the growth of the global engineered T cells market.

Advancements in immunotherapy research have deepened our understanding of the human immune system's intricate workings. Scientists have unraveled the complexities of immune responses, paving the way for the development of innovative therapies. Engineered T cell therapies are the product of this newfound knowledge, allowing researchers to harness the immune system's power for targeted disease treatment.

Immunotherapy research has ushered in an era of precision medicine. Tailoring treatments to individual patients based on their unique genetic makeup and the molecular characteristics of their diseases has become a reality. Engineered T cell therapies exemplify this approach, as they can be customized to recognize specific antigens present on cancer cells or pathogens, sparing healthy cells and minimizing side effects.

Originally designed for cancer treatment, engineered T cell therapies are now finding applications in other disease areas. Researchers are exploring their potential in autoimmune disorders and infectious diseases. Advancements in understanding the immune system's role in various diseases are driving this expansion, broadening the scope of the engineered T cells market.

Immunotherapy research has led to substantial improvements in the safety profiles of engineered T cell therapies. Early iterations of CAR-T therapies were associated with severe side effects, but ongoing research has refined their design and administration protocols. This progress in safety has increased patient confidence and expanded the pool of eligible candidates for these therapies.

Immunotherapy research has provided insights into the identification and validation of new therapeutic targets. This knowledge is instrumental in the development of engineered T cell therapies. As researchers uncover novel antigens and markers associated with diseases, they can design T cells that precisely target these elements, thereby increasing the therapies' effectiveness.

Success in Treating Hematological Cancers

The success stories emerging from the treatment of hematological cancers have been nothing short of remarkable. Pioneering therapies, particularly CAR-T (Chimeric Antigen Receptor T-cell) and TCR-T (T-cell Receptor T-cell) therapies, have demonstrated exceptional efficacy in combating blood-related malignancies. This success is not only transforming the outlook for patients but also serving as a driving force behind the rapid growth of the global engineered T cells market.

Engineered T cell therapies have demonstrated unprecedented efficacy in treating hematological cancers, such as leukemia and lymphoma. Clinical trials have reported remarkable response rates and long-lasting remissions in patients who had exhausted conventional treatment options. Such results are reshaping the treatment landscape and instilling confidence in the potential of engineered T cell therapies.

Hematological cancers, particularly some forms of leukemia, were historically considered difficult to treat, especially in relapsed or refractory cases. Engineered T cell therapies are changing that narrative by offering viable treatment options for patients who had few or no alternatives. This success is drawing attention from the medical community and increasing demand for these therapies.

As more patients experience positive outcomes with engineered T cell therapies, there is growing advocacy for broader patient access. Healthcare providers, patient advocacy groups, and policymakers are recognizing the transformative potential of these treatments and are working to ensure that they are accessible to a wider patient population. This push for accessibility is a significant driver of market growth.

Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have granted approvals for CAR-T therapies to treat certain hematological cancers. These approvals serve as a critical stamp of validation, boosting confidence in the therapies' efficacy and safety. They also expedite market entry and commercialization.

While the initial focus of engineered T cell therapies was hematological cancers, ongoing research is expanding their indications. Scientists are investigating their potential in treating other blood disorders and solid tumors. This diversification of applications is not only broadening the market but also increasing the potential patient pool.

The success in treating hematological cancers with engineered T cell therapies has attracted substantial investments in research and development. Pharmaceutical companies, biotechnology firms, and academic institutions are pouring resources into advancing these therapies. This influx of capital is driving innovation, accelerating clinical trials, and expanding the market.

Clinical trials and commercialization efforts for engineered T cell therapies have expanded globally. This international reach ensures that patients worldwide can benefit from these groundbreaking treatments. The global market expansion is opening up new opportunities and driving growth.

Expanding Indications

Engineered T cell therapies, including CAR-T (Chimeric Antigen Receptor T-cell) and TCR-T (T-cell Receptor T-cell) therapies, have made remarkable strides in the treatment of various diseases, most notably hematological cancers. However, their potential extends far beyond their initial applications. The ongoing exploration of expanded indications is emerging as a powerful driver for the growth of the global engineered T cells market.

The expansion of indications for engineered T cell therapies represents a significant breakthrough in modern medicine. These therapies have the potential to diversify treatment options for patients across a broad spectrum of diseases, both in oncology and beyond. As new indications emerge, patients previously lacking effective treatments can now find hope in these innovative therapies.

While engineered T cell therapies initially gained prominence in treating blood-related cancers, researchers have been diligently working to apply these treatments to solid tumors. Success in this area would represent a major paradigm shift in oncology, expanding the addressable patient population exponentially. Engineered T cells have demonstrated promise in clinical trials targeting a range of solid tumor types, including lung, breast, and prostate cancer.

Another exciting avenue of exploration for engineered T cell therapies is the treatment of autoimmune diseases. By reprogramming T cells to regulate the immune response, these therapies hold the potential to alleviate the symptoms and halt the progression of conditions such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease. Success in this area could dramatically improve the quality of life for millions of patients.

Engineered T cell therapies are also being investigated as a means of combatting infectious diseases. Researchers are exploring ways to modify T cells to target viruses such as HIV and hepatitis. These therapies have the potential not only to treat infections directly but also to enhance the body's immune response, offering a multifaceted approach to viral diseases.

Rare diseases often present unique challenges in terms of treatment development. Engineered T cell therapies, with their adaptability and precision, offer a promising avenue for addressing rare genetic disorders. The ability to customize these therapies to target specific genetic mutations holds great potential for improving the lives of individuals with rare diseases.

Expanded indications for engineered T cell therapies are particularly promising for pediatric patients. Many children suffer from rare and aggressive forms of cancer, autoimmune diseases, and genetic disorders. Engineered T cell therapies offer a ray of hope for these young patients who may have exhausted conventional treatment options.

The exploration of expanded indications has attracted significant investment from pharmaceutical companies, venture capitalists, and research institutions. The potential to apply these therapies across a broader spectrum of diseases has fueled innovation and accelerated the development of new treatment modalities. This influx of capital is driving market growth and supporting the advancement of engineered T cell technologies.

Increasing Investment

The global engineered T cells market, characterized by groundbreaking therapies like CAR-T (Chimeric Antigen Receptor T-cell) and TCR-T (T-cell Receptor T-cell), is on a trajectory of rapid expansion. An essential driver behind this growth is the substantial and increasing investment pouring into research, development, and commercialization efforts. This infusion of capital is not only advancing science but also propelling the market forward.

Investment in the engineered T cells market translates into more funding for research and development. With increased resources, scientists and researchers can push the boundaries of what is possible, leading to more profound insights into the underlying biology, innovative technologies, and enhanced treatment modalities. Advancements in research drive the market's growth by expanding the scope and effectiveness of engineered T cell therapies.

Clinical trials are a critical phase in bringing engineered T cell therapies to patients. Investment enables pharmaceutical companies and biotech firms to conduct larger and more extensive clinical trials. Accelerated trials mean quicker results, which can lead to regulatory approvals and commercialization sooner, benefiting both patients and market growth.

Building and maintaining the specialized infrastructure required for engineered T cell therapy production and administration is a capital-intensive process. Increased investment supports the establishment and expansion of manufacturing facilities, cleanrooms, and distribution networks. Having robust infrastructure in place ensures that these therapies can reach a broader patient population, fostering market growth.

Investment drives innovation in manufacturing processes. Automation, scalability, and efficiency improvements can significantly reduce the cost of producing engineered T cell therapies. As production becomes more cost-effective, therapies can become more accessible, attracting a larger market share.

The engineered T cells field relies on top-tier talent, including scientists, researchers, clinicians, and manufacturing experts. Increased investment not only provides the funding to attract and retain these professionals but also fosters a culture of innovation and excellence. This, in turn, accelerates progress and fuels the market's growth.

Key Market Challenges

Manufacturing Complexity

The manufacturing of engineered T cell therapies is intricate and requires stringent quality control. Maintaining the viability and functionality of T cells during the manufacturing process is critical. Scaling up production to meet the demand for these therapies can be challenging, and any variation in manufacturing conditions can impact treatment efficacy.

Safety Concerns

While engineered T cell therapies have shown remarkable efficacy, they are not without safety concerns. Cytokine release syndrome (CRS) and neurologic toxicities are known side effects, and in some cases, these adverse events can be severe. Striking the right balance between maximizing the therapeutic effect and minimizing side effects remains a significant challenge.

Limited Target Antigens

The success of CAR-T therapies relies on the identification of specific target antigens present on cancer cells. Finding suitable antigens for all types of cancer can be challenging, limiting the range of cancers that can be effectively treated with engineered T cells. Expanding the repertoire of target antigens is essential for the market's growth.

Key Market Trends

Expansion into Solid Tumors

While CAR-T therapies initially gained prominence in treating hematological cancers, researchers are increasingly focused on expanding their applications to solid tumors. Emerging clinical trials and research efforts are exploring ways to overcome the unique challenges of treating solid tumors with engineered T cells, offering hope to a broader range of cancer patients.

Combination Therapies

Combination therapies that integrate engineered T cell therapies with other treatment modalities, such as checkpoint inhibitors, targeted therapies, or traditional chemotherapy, are gaining momentum. These synergistic approaches are expected to improve treatment outcomes and reduce the risk of resistance, making them a key trend to watch.

Gene Editing Techniques

Advancements in gene editing techniques, such as CRISPR-Cas9, are enabling researchers to refine engineered T cells with greater precision. This trend is expected to enhance the effectiveness and safety of these therapies.

Segmental Insights

Type Insights

Based on the category of Type, it is anticipated that the chimeric antigen receptor (CAR) modified T cells segment will dominate the market for engineered T cells in the projected period in 2022. CAR-T cell therapy represents an innovative approach to tumor immunotherapy in cancer treatment. It is widely recognized for its effectiveness in treating acute B lymphocytic leukemia, and numerous clinical trials have been conducted using CAR-T cell therapy for various cancer types. This approach is highly specialized and adaptable because it allows for the modification of the antigen-binding region to target different tumor markers.

Furthermore, CAR-T cells have the capacity to create lasting immune memories in patients with advanced leukemia. CARs, which are recombinant receptors, bind to tumor antigens and activate T cells. These CAR-T cells can directly recognize tumor-specific antigens on the surface of cancer cells and multiply, leading to the destruction of tumor cells. Each patient can receive a personalized CAR T-cell therapy by collecting their T cells and genetically engineering them to express chimeric antigen receptors (CARs) on their cell surfaces. CARs enable the identification and binding to antigens or proteins on the outermost layer of cancer cells.

The segment involving T cell receptor (TCR) modified T cells is also expected to experience significant growth in the engineered T cells market during the forecasted period. TCR-modified T-cell therapy can be tailored to a patient's specific malignancy by identifying unique tumor antigens. This personalized approach enhances treatment effectiveness and reduces the risk of resistance to treatment. TCRs are more specialized as they target intracellular antigens crucial for tumor growth. This precision minimizes harm to healthy cells and reduces the chances of unintended side effects.

Moreover, TCR-modified T-cells can be combined with other treatments, such as checkpoint inhibitors, to enhance their efficacy. This synergistic potential opens up opportunities for combination therapy that can address multiple aspects of cancer. Thanks to their heightened specificity and antigen recognition capabilities, TCR-modified T-cells may provide more substantial and long-lasting responses compared to previous therapies.

Application Insights

Based on Application, it is anticipated that the lung cancer segment will assert dominance in the engineered T cells market in the projected period. Engineered T cells offer a promising avenue for the treatment of lung cancer and various other malignancies, as they can be tailored to target and combat cancer cells within the body. The field of T-cell therapies has evolved significantly through ongoing research and development endeavors, presenting potential benefits for patients with lung cancer and the broader domain of immunotherapy.

To illustrate, taking into account the American Cancer Society's estimates for lung cancer in the United States in 2023, it is anticipated that there will be approximately 117,550 new cases of this disease, with the majority (117,340) occurring in males. Additionally, the projections indicate around 120,790 deaths related to lung cancer, with a significant number (59,910) occurring among women.

On the other hand, breast cancer emerges as the fastest-growing segment in the engineered T cells market during the forecasted period. Innovative treatments such as CAR-T cell therapies are demonstrating promising outcomes in clinical trials and have the potential to revolutionize the landscape of cancer treatment. The expansion of the market can be attributed to the increasing demand for more effective therapies for breast cancer, heightened investments in research, and advancements in scientific research that are driving progress in this field.

Regional Insights

In 2022, North America held the largest share of revenue in the engineered T cells market, and this dominant position is expected to persist throughout the projected period. North America is home to some of the world's leading pharmaceutical and biotechnology firms. These companies have made substantial investments in the research of modified T cells, paving the way for groundbreaking treatments and tools. The healthcare system in North America is well-established and boasts prestigious hospitals, clinics, and medical research facilities. This robust infrastructure facilitates the development and testing of new treatments, including modified T cells, in patients.

Venture capital firms, private equity investors, and government programs have injected significant financial support into biotech and medical research in North America. This funding has facilitated the growth of both emerging and established businesses engaged in the development of modified T-cell treatments.

According to data from the National Cancer Institute, breast cancer is the most prevalent cancer type, with an anticipated 300,590 new cases in the United States in 2023. Cellular therapies, including modified T cells, have been developed and approved with the assistance of the US Food and Drug Administration (FDA). The accelerated review processes and simplified regulatory pathways in the region have encouraged companies to focus their research efforts in North America.

Meanwhile, the Asia Pacific region is poised to experience the fastest growth in the engineered T cells market during the forecasted period. The increasing incidence of cancer and other chronic diseases in Asia has elevated the demand for innovative and personalized therapies like modified T-cell treatments. The vast and diverse population of the Asia Pacific region provides a substantial pool of patients for clinical trials and the adoption of these treatments. Moreover, developed nations such as China, Japan, South Korea, and India have been actively developing and marketing engineered T-cell therapies due to enhancements in healthcare infrastructure and biotechnology research capabilities.

Key Market Players

• Amgen Inc

• Athenex, Inc.

• Bellicum Pharmaceuticals Inc

• Bristol-Myers Squibb Co

• Eli Lilly & Co

• Gilead Sciences Inc

• Novartis AG

• Oxford Biomedica PLC

• Pfizer Inc

• Precision BioSciences Inc

Report Scope:

In this report, the Global Engineered T Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Engineered T Cells Market, By Type:

• Chimeric Antigen Receptor
• T Cell Receptor
• Tumor-Infiltrating Lymphocytes

Engineered T Cells Market, By Application:

• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Melanoma

Engineered T Cells Market, By End-User:

• Cancer Research Centers
• Clinics
• Hospitals
• Others

Engineered T Cells Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Engineered T Cells Market.

Available Customizations:

• Global Engineered T Cells market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Engineered T Cells Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 5.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 5.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Type
  • 5.3.2. By Application
  • 5.3.3. By End-User
  • 5.3.4. By Region

6. North America Engineered T Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 6.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 6.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Engineered T Cells Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Engineered T Cells Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Engineered T Cells Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-User

7. Europe Engineered T Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 7.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 7.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Engineered T Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-User
  • 7.3.2. United Kingdom Engineered T Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-User
  • 7.3.3. France Engineered T Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Engineered T Cells Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Engineered T Cells Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-User

8. Asia-Pacific Engineered T Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 8.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 8.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Engineered T Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-User
  • 8.3.2. Japan Engineered T Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-User
  • 8.3.3. India Engineered T Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-User
  • 8.3.4. Australia Engineered T Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-User
  • 8.3.5. South Korea Engineered T Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-User

9. South America Engineered T Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 9.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 9.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Engineered T Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Engineered T Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Engineered T Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Engineered T Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes)
  • 10.2.2. By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Melanoma)
  • 10.2.3. By End-User (Cancer Research Centers, Clinics, Hospitals, Others)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Engineered T Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Engineered T Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Engineered T Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-User
  • 10.3.4. Kuwait Engineered T Cells Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Type
      • 10.3.4.2.2. By Application
      • 10.3.4.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Amgen Inc
  • 14.6.2. Athenex, Inc.
  • 14.6.3. Bellicum Pharmaceuticals Inc
  • 14.6.4. Bristol-Myers Squibb Co
  • 14.6.5. Eli Lilly & Co
  • 14.6.6. Gilead Sciences Inc
  • 14.6.7. Novartis AG
  • 14.6.8. Oxford Biomedica PLC
  • 14.6.9. Pfizer Inc
  • 14.6.10. Precision BioSciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer